[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100621787":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":13,"locations":7,"responsibleParty":22,"collaborators":7,"id":24,"slug":25,"hasResults":26,"nctId":27,"briefTitle":28,"officialTitle":29,"acronym":30,"eligibilityCriteria":31,"healthyVolunteers":26,"sex":32,"minAge":33,"maxAge":7,"enrollmentInfo":34,"targetDuration":7,"studyType":37,"phases":7,"briefSummary":38,"conditions":39,"keywords":43,"overallStatus":49,"whyStopped":7,"lastUpdateSubmitDate":50,"lastUpdatePostDateStruct":51,"startDateStruct":54,"completionDateStruct":56,"leadSponsor":58,"locationsCount":7},{"fullName":5,"class":6},"Cellution Biologics","INDUSTRY",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"BIOLOGICAL","dHPT, AIC","Sterile dehydrated Human Amnion - Intermediate Layer - Chorion Membrane Allograft",[14,19],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},"Bryanna Finstein","CONTACT","6035574660","bryanna.f@cellutionbiologics.com",{"name":20,"role":16,"phone":17,"phoneExt":7,"email":21},"Cellution Research","clinical@cellutionbiologics.com",{"type":23,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100621787","evaluation-of-the-safety-and-efficacy-of-dehydrated-human-placenta-tissue-dhpt-for-wound-healing-100621787",false,"NCT07375160","Evaluation of the Safety and Efficacy of Dehydrated Human Placenta Tissue (dHPT) for Wound Healing","A Retrospective, Real World Evidence (RWE) Trial to Evaluate the Safety and Efficacy of a Dehydrated Human Placenta Tissue (dHPT) for Wound Healing","RETRO-PLAST","Inclusion Criteria:\n\n* 18 years of age or older.\n* Wound treated with Cellution Biologics AmchoPlast, a dehydrated human placental tissue (dHPT).\n* Wound present for greater than or equal to 30 days prior to treatment with dHPT.\n* Wound is not infected.\n* Wound surface area is greater than 1cm2 at initial assessment.\n* Clinical documentation of wound treatment.\n\nExclusion Criteria:\n\n* AmchoPlast dHPT product was not applied to wound.\n* HbA1C \\>12%.\n* Presence of active osteomyelitis.\n* Concurrent treatment for malignant disease.\n* Use of other advanced biologics during treatment period.","ALL","18 Years",{"count":35,"type":36},300,"ESTIMATED","OBSERVATIONAL","The retrospective trial is observational, intended to stand alone, complement and integrate data collected in ongoing clinical studies to aid in establishing payor coverage in the United States (U.S.) for Cellution Biologics allograft products with real-world evidence to support the clinical adoption in patients to manage chronic or surgical wounds.",[40,41,42],"Diabetic Foot Ulcer (DFU)","Venous Leg Ulcer (VLU)","Pressure Ulcer (PU)",[44,45,46,47,48],"Chronic Wound","Leg Wound","Amniotic","Allograft","Placenta","NOT_YET_RECRUITING","2026-02-27",{"date":52,"type":53},"2026-03-03","ACTUAL",{"date":55,"type":36},"2026-04",{"date":57,"type":36},"2026-12",{"name":5,"class":6}]